This looks like an interesting play to me. Expect positive news...

This looks like an interesting play to me. Expect positive news flow moving forward and media attention as they present at a number of industry conferences/seminar's over the next few months. IMV it justifies a valuation > current $6m mkt cap given they are testing 10-12 of the top drugs sold in the world to see if their platform delivers it in a more efficient manner than current administration techniques. Looking at some of the others working in the same space (PSD, ACR, POH Mkt cap: $260m, $96m and $58m respectively) could see rapid escalation in share price in my view.
Also, unlike drug companies, there technology is a device for administration so doesn't take anywhere near as long to do testing to gain approval.

I hold OBJ.

Do your own research but I think looks good.